Drug treatment and novel drug target against Cryptosporidium.
Cryptosporidiosis emergence triggered the screening of many compounds for potential anti-cryptosporidial activity in which the majority were ineffective. The outbreak of cryptosporidiosis which occurred in Milwaukee in 1993 was not only the first significant emergence of Cryptosporidium spp. as a major human pathogen but also a huge waterborne outbreak thickening thousands of people from a major city in North America. Since then, outbreaks of cryptosporidiosis are regularly occurring throughout the world. New drugs against this parasite became consequently urgently needed. Among the most commonly used treatments against cryptosporidiosis are paromomycin, and azithromycin, which are partially effective. Nitazoxanide (NTZ)'s effectiveness was demonstrated in vitro, and in vivo using several animal models and finally in clinical trials. It significantly shortened the duration of diarrhea and decreased mortality in adults and in malnourished children. NTZ is not effective without an appropriate immune response. In AIDS patients, combination therapy restoring immunity along with antimicrobial treatment of Cryptosporidium infection is necessary. Recent investigations focused on the potential of molecular-based immunotherapy against this parasite. Others tested the effects of probiotic bacteria, but were unable to demonstrate eradication of C. parvum. New synthetic isoflavone derivatives demonstrated excellent activity against C. parvum in vitro and in a gerbil model of infection. Newly synthesized nitro- or non nitro- thiazolide compounds, derived from NTZ, have been recently shown to be at least as effective as NTZ against C. parvum in vitro development and are promising new therapeutic agents.
Gargala
G
G
Laboratory of Parasitology, ADEN EA-3234, Faculty of Medicine and Pharmacy, Rouen University, 22, Boulevard Gambetta, F-76183 Rouen Cedex, France. gilles.gargala@univ-rouen.fr
D000818:Animals; D003049:Coccidiostats / Q000627:therapeutic use*; D003457:Cryptosporidiosis / Q000188:drug therapy*; D003458:Cryptosporidium / Q000187:drug effects* / Q000254:growth & development; D003967:Diarrhea / Q000188:drug therapy / Q000469:parasitology; D004196:Disease Outbreaks; D006801:Humans; D009574:Nitro Compounds; D013844:Thiazoles / Q000627:therapeutic use; D016896:Treatment Outcome
D003049:Coccidiostats; D009574:Nitro Compounds; D013844:Thiazoles; C041747:nitazoxanide